Literature DB >> 18761267

Relationship of sustained brain natriuretic peptide release after reperfused acute myocardial infarction with gated SPECT infarct measurements and its connection with collagen turnover and left ventricular remodeling.

Giampaolo Cerisano1, Renato Valenti, Roberto Sciagrà, Paolo Domenico Pucci, Mariasilvia Tommasi, Silvia Raspanti, Alberto Pupi, Emilio Vincenzo Dovellini, David Antoniucci.   

Abstract

BACKGROUND: The relationship among plasma brain natriuretic peptide (BNP), markers of extracellular matrix (ECM) remodeling, and left ventricular (LV) dilation after reperfused acute myocardial infarction is poorly known. METHODS AND
RESULTS: Echocardiogram, plasma BNP, and ECM degradation markers (serum amino-terminal telopeptide of type I procollagen and type III procollagen and carboxy-terminal telopeptide of type I procollagen [ICTP]) were evaluated in 34 patients at days 1, 3, and 30 after first reperfused acute myocardial infarction. At 1 month, infarct size and severity and LV volume were measured by sestamibi gated single photon emission computed tomography. Patients were stratified according to day 3 BNP levels into 2 groups: group 1 (n = 17) had BNP values over the median value, and group 2 (n = 17) had BNP values under the median value. Infarct size and severity were similar in the 2 groups. LV volumes increased in group 1 but decreased in group 2 (P < .01). BNP values, LV volume/mass index, and infarct size were independent predictors of 1-month LV dilation (beta = .58 [P = .001], beta = .41 [P = .01], and beta = .32 [P = .03], respectively). Levels of serum amino-terminal propeptide of type I procollagen and type III procollagen were similar in both groups. The level of ICTP increased significantly in group 1 only, and after 3 days, it was higher (P < .01) than in group 2. In group 1 ICTP significantly interacted with the relationship between BNP release and serial changes in LV volumes (F = 4.87, P = .03).
CONCLUSIONS: ICTP is related to elevated BNP level independently of infarct size and severity and interacts with the relationship between BNP and LV dilation. BNP levels could play a role in LV remodeling by favoring ECM degradation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18761267     DOI: 10.1016/j.nuclcard.2008.06.009

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  41 in total

Review 1.  Infarct size measured by single photon emission computed tomographic imaging with (99m)Tc-sestamibi: A measure of the efficacy of therapy in acute myocardial infarction.

Authors:  R J Gibbons; T D Miller; T F Christian
Journal:  Circulation       Date:  2000 Jan 4-11       Impact factor: 29.690

2.  Diagnostic value of contrast-enhanced magnetic resonance imaging and single-photon emission computed tomography for detection of myocardial necrosis early after acute myocardial infarction.

Authors:  Tareq Ibrahim; Hubertus P Bülow; Thomas Hackl; Mira Hörnke; Stephan G Nekolla; Martin Breuer; Albert Schömig; Markus Schwaiger
Journal:  J Am Coll Cardiol       Date:  2006-12-29       Impact factor: 24.094

3.  Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction.

Authors:  S H Poulsen; N B Høst; S E Jensen; K Egstrup
Journal:  Circulation       Date:  2000-04-04       Impact factor: 29.690

4.  Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice.

Authors:  L E Rohde; A Ducharme; L H Arroyo; M Aikawa; G H Sukhova; A Lopez-Anaya; K F McClure; P G Mitchell; P Libby; R T Lee
Journal:  Circulation       Date:  1999-06-15       Impact factor: 29.690

5.  Determinants of infarct size in reperfusion therapy for acute myocardial infarction.

Authors:  T F Christian; R S Schwartz; R J Gibbons
Journal:  Circulation       Date:  1992-07       Impact factor: 29.690

6.  N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction.

Authors:  Dimitrios N Tziakas; Georgios K Chalikias; Eleni I Hatzinikolaou; Dimitrios A Stakos; Ioannis K Tentes; Alexandros Kortsaris; Dimitrios I Hatseras; Juan Carlos Kaski
Journal:  Am J Cardiol       Date:  2005-07-01       Impact factor: 2.778

7.  In vitro validation of a simple tomographic technique for estimation of percentage myocardium at risk using methoxyisobutyl isonitrile technetium 99m (sestamibi).

Authors:  M K O'Connor; T Hammell; R J Gibbons
Journal:  Eur J Nucl Med       Date:  1990

8.  Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis. Results of the GISSI-2 data base. The Ad hoc Working Group of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-2 Data Base.

Authors:  A Volpi; C De Vita; M G Franzosi; E Geraci; A P Maggioni; F Mauri; E Negri; E Santoro; L Tavazzi; G Tognoni
Journal:  Circulation       Date:  1993-08       Impact factor: 29.690

9.  B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction.

Authors:  A Mark Richards; M Gary Nicholls; Eric A Espiner; John G Lainchbury; Richard W Troughton; John Elliott; Christopher Frampton; John Turner; Ian G Crozier; Timothy G Yandle
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

10.  Atrial natriuretic peptide, B-type natriuretic peptide, and serum collagen markers after acute myocardial infarction.

Authors:  Jarkko Magga; Mikko Puhakka; Seppo Hietakorpi; Kari Punnonen; Paavo Uusimaa; Juha Risteli; Olli Vuolteenaho; Heikki Ruskoaho; Keijo Peuhkurinen
Journal:  J Appl Physiol (1985)       Date:  2003-11-07
View more
  2 in total

1.  The past as prologue.

Authors:  Timothy F Christian
Journal:  J Nucl Cardiol       Date:  2008 Sep-Oct       Impact factor: 5.952

2.  Evaluation of heart function with impedance cardiography in acute myocardial infarction patients.

Authors:  Shun-Juan Chen; Zhu Gong; Qiang-Lin Duan
Journal:  Int J Clin Exp Med       Date:  2014-03-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.